11:15:03 EDT Tue 28 Mar 2023
Enter Symbol
or Name

Login ID:

News for U:TCBP from 2022-03-29 to 2023-03-28 - 32 items News ReleasesIn The NewsOther CAUS
2023-03-28 08:05U:TCBPNews ReleaseTC BioPharm Announces Pricing of $5.5 Million Public Offering
2023-03-22 08:30U:TCBPNews ReleaseTC Biopharm Announces Corporate Restructuring, Reduction in Overhead
2023-03-16 12:00U:TCBPNews ReleaseTC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)
2023-03-07 08:30U:TCBPNews ReleaseTC BioPharm Shifts Focus to FDA Clinical Trials
2023-02-23 08:30U:TCBPNews ReleaseTC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
2023-02-21 08:30U:TCBPNews ReleaseTC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
2023-02-14 08:30U:TCBPNews ReleaseTC BioPharm Announces New Chair of the Board, Arlene Morris
2023-02-13 16:15U:TCBPNews ReleaseTC BioPharm to Reschedule Shareholder Update Call and Webcast
2023-02-07 08:30U:TCBPNews ReleaseTC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort
2023-01-30 08:30U:TCBPNews ReleaseTC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
2023-01-20 08:30U:TCBPNews ReleaseTC BioPharm to Host Shareholder Update Call
2023-01-19 08:30U:TCBPNews ReleaseTC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)
2023-01-17 08:30U:TCBPNews ReleaseTC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
2022-12-12 09:00U:TCBPNews ReleaseTC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update
2022-11-30 18:43U:TCBPNews ReleaseTC BioPharm Announces Closing of $7.35 Million Private Placement
2022-11-28 08:00U:TCBPNews ReleaseTC BioPharm Announces $7.35 Million Private Placement
2022-11-22 08:00U:TCBPNews ReleaseTC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune ‚ ®, in Patients with Acute Myeloid Leukemia
2022-10-26 08:30U:TCBPNews ReleaseTC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise
2022-10-03 08:30U:TCBPNews ReleaseTC BioPharm to Present at Upcoming Investor Conferences
2022-09-13 09:30U:TCBPNews ReleaseTC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune(TM)
2022-08-22 08:30U:TCBPNews ReleaseTC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-07-25 08:30U:TCBPNews ReleaseTC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit
2022-07-08 08:30U:TCBPNews ReleaseTC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"
2022-06-07 16:00U:TCBPNews ReleaseTC Biopharm Announces Closing of $4 Million Underwritten Public Offering
2022-06-02 18:10U:TCBPNews ReleaseTC BioPharm Announces Pricing of $4 Million Underwritten Public Offering
2022-05-31 10:00U:TCBPNews ReleaseTC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally
2022-05-23 08:30U:TCBPNews ReleaseKuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market
2022-05-18 08:30U:TCBPNews ReleaseTC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts
2022-05-03 08:30U:TCBPNews ReleaseTC BioPharm Invited to Present at LD Micro Conference
2022-04-26 08:45U:TCBPNews ReleaseTC BioPharm to Participate in Upcoming Conferences
2022-04-21 08:00U:TCBPNews ReleaseTC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day
2022-04-06 08:30U:TCBPNews ReleaseTC BioPharm Receives CryoTC(TM) Trademark for Proprietary Cell Freezing Process